相关实验视频

Updated: Jul 18, 2026

In Vitro Aggregation Assays Using Hyperphosphorylated Tau Protein
09:22

In Vitro Aggregation Assays Using Hyperphosphorylated Tau Protein

Published on: January 2, 2015

18.4K

在主观认知衰退中与-Tau181相关,但在对照病例中没有

Sofia Egebäck Arulf1, Robin Ziyue Zhou1, Bjørn-Eivind Kirsebom2,3,4,5

  • 1Department of Neurobiology, Division of Neurogeriatrics, Care Sciences and Society, Center for Alzheimer Research, Karolinska Institutet, Solna, Sweden.

Journal of Alzheimer's disease : JAD
|August 9, 2024
PubMed
概括

在脑脊液中切割N-乙葡萄糖胺 (切割GlcNAc) 与阿尔茨海默病早期的生物标志物相关. 这种甘氨酸可以作为认知衰退的预测生物标志物,即使是在临床前阶段.

关键词:
阿尔茨海默氏症是阿尔茨海默氏症的一种疾病.在N-glycosylation的过程中.切割N-乙葡萄糖胺的两个部分.痴呆症 痴呆症是一种痴呆症.轻度的认知障碍 轻度的认知障碍酸-tau是一种酸盐.主观认知衰退 主观认知衰退总的tau总的tau.

更多相关视频

Assay for Phosphorylation and Microtubule Binding Along with Localization of Tau Protein in Colorectal Cancer Cells12:55

Assay for Phosphorylation and Microtubule Binding Along with Localization of Tau Protein in Colorectal Cancer Cells

Published on: October 10, 2017

8.9K
Modulation of Tau Subcellular Localization as a Tool to Investigate the Expression of Disease-related Genes09:12

Modulation of Tau Subcellular Localization as a Tool to Investigate the Expression of Disease-related Genes

Published on: December 20, 2019

6.3K

相关概念视频

Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
Alzheimer Disease ll: Pathophysiology01:23

Alzheimer Disease ll: Pathophysiology

Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...